[Federal Register Volume 71, Number 162 (Tuesday, August 22, 2006)]
[Notices]
[Page 48947]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-13838]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on November 2, 2005, Noramco 
Inc., Division of Ortho-McNeil, Inc., 500 Old Swedes Landing Road, 
Wilmington, Delaware 19801, made application by renewal, and by letter, 
to the Drug Enforcement Administration (DEA) for registration as a bulk 
manufacturer of the basic classes of controlled substances listed in 
Schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Morphine-N-Oxide (9307).....................  I
Codeine-N-Oxide (9053)......................   I
Dihydromorphine (9145)......................   II
Amphetamine (1100)..........................   II
Methylphenidate (1724)......................   II
Codeine (9050)..............................   II
Dihydrocodeine (9120).......................   II
Oxycodone (9143)............................   II
Hydrocodone (9193)..........................   II
Morphine (9300).............................   II
Thebaine (9333).............................   II
Oxymorphone (9652)..........................   II
------------------------------------------------------------------------

    The company plans to bulk manufacture the above listed controlled 
substances for sale and distribution to manufacturers for product 
development and formulation.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative/ODL; or any being sent via express mail should be sent 
to DEA Headquarters, Attention: DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must 
be filed no later than October 23, 2006.

    Dated: August 15, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E6-13838 Filed 8-21-06; 8:45 am]
BILLING CODE 4410-09-P